The androgen receptor (AR) plays an essential role in prostate cancer, and suppression of its signaling with androgen deprivation therapy (ADT) has been the mainstay of treatment for metastatic hormone-sensitive prostate cancer for more than 70 y. Chemotherapy has been reserved for metastatic castration-resistant prostate cancer (mCRPC). The Eastern Cooperative Oncology Group-led trial E3805: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) showed that the addition of docetaxel to ADT prolonged overall survival compared with ADT alone in patients with metastatic hormone-sensitive prostate cancer. This finding suggests that there is an interaction between AR signaling activity and docetaxel sensitivity. Here we demonstrate that the prostate cancer cell lines LNCaP and LAPC4 display markedly different sensitivity to docetaxel with AR activation, and RNA-seq analysis of these cell lines identified KDM5D (lysine-specific demethylase 5D) encoded on the Y chromosome as a potential mediator of this sensitivity. Knocking down KDM5D expression in LNCaP leads to docetaxel resistance in the presence of dihydrotestosterone. KDM5D physically interacts with AR in the nucleus, and regulates its transcriptional activity by demethylating H3K4me3 active transcriptional marks. Attenuating KDM5D expression dysregulates AR signaling, resulting in docetaxel insensitivity. KDM5D deletion was also observed in the LNCaP-derived CRPC cell line 104R2, which displayed docetaxel insensitivity with AR activation, unlike parental LNCaP. Dataset analysis from the Oncomine database revealed significantly decreased KDM5D expression in CRPC and poorer prognosis with low KDM5D expression. Taking these data together, this work indicates that KDM5D modulates the AR axis and that this is associated with altered docetaxel sensitivity.
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prostate cancer | docetaxel | KDM5D | JARID1D | androgen receptor D ocetaxel has been an important treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) since 2004, when phase 3 trials demonstrated a 2-to 3-mo prolongation of overall survival (OS) compared with mitoxantrone and prednisone (1, 2) . However, nearly all CRPC patients treated with docetaxel eventually become refractory, due to the development of drug resistance. In 2014, the Eastern Cooperative Oncology Group-led trial E3805: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) showed that docetaxel given at the time of androgen deprivation therapy (ADT) initiation for metastatic hormone-sensitive prostate cancer (mHSPC) improved OS by 13 mo from 44 to 57 mo (3) . These findings were confirmed in 2015 by the Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial (4) . However, it still remains unclear why docetaxel deployed with concurrent androgen receptor (AR) inhibition for mHSPC improves OS dramatically more than for CRPC.
A recent study revealed a high frequency of AR signaling alterations in CRPC compared with primary HSPC, indicating the existence of AR reprogramming in CRPC (5) . In this study, we hypothesized that modulation of AR signaling at the time of ADT initiation in mHSPC may enhance the efficacy of docetaxel in some patients, and that AR reprogramming in CRPC may subsequently influence the sensitivity of prostate cancer cells to docetaxel. We identified KDM5D (lysine-specific demethylase 5D; JARID1D), which is encoded on the Y chromosome, as a determinant of docetaxel sensitivity through its interaction with AR signaling in prostate cancer cells.
Results

AR Signaling Impacts Docetaxel Sensitivity in a Cell Line-Dependent
Manner. To interrogate the sensitivity of docetaxel in prostate cancer cells, we first examined cell growth with exposure to docetaxel in a panel of prostate cancer cell lines (Fig. 1A) . The hormone-sensitive AR-positive prostate cancer cell lines LNCaP and LAPC4 were further analyzed because they displayed markedly different docetaxel sensitivities in 10% FBS medium. The GI 50 (concentration of docetaxel necessary for 50% maximal inhibition of cell proliferation) of LAPC4 (9.17 ± 2.04 nM) was approximately ninefold higher than that of LNCaP (0.98 ± 0.24 nM). Notably, despite AR stimulation in both cell lines, confirmed by examining phosphorylated AR (Fig. S1A) , the docetaxel sensitivity of these two cell lines was markedly different after exposure to dihydrotestosterone (DHT); the addition of DHT desensitized LAPC4 to docetaxel
Significance
The results of the recent clinical trials, ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) and Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE), suggest a significant contribution of androgen receptor signaling to sensitivity of docetaxel in prostate cancer. This study provides evidence that KDM5D (lysine-specific demethylase 5D) encoded on the Y chromosome plays an important role in docetaxel sensitivity by interacting with androgen receptor signaling, and that its expression level is associated with clinical outcomes. These data start to elucidate the biological underpinnings for the findings from these clinical trials.
treatment (GI 50 increased by ∼100-fold) but not LNCaP (Fig. 1B and Fig. S1B ), and the impact of DHT treatment on the docetaxel sensitivity of LAPC4 was dose-dependent (Fig. 1C) . We also confirmed that DHT treatment of LAPC4 inhibited docetaxel-induced apoptosis, resulting in the reduced effect on cell proliferation, whereas docetaxel-induced poly(ADP-ribose) polymerase (PARP) cleavage was prominent in LNCaP regardless of DHT induction (Fig. S1C) . We therefore hypothesized that a careful comparison of these cell lines in the presence and absence of DHT would create an excellent model to understand the molecular underpinnings of the widely divergent sensitivities of HSPC and CRPC to docetaxel.
To demonstrate that the DHT-induced docetaxel resistance in LAPC4 is mediated by AR signaling, we examined whether blocking AR activity in LAPC4 by enzalutamide, an AR antagonist, could inhibit DHT-induced docetaxel insensitivity. Despite the presence of a physiologically high concentration of docetaxel (10 nM) (6), LAPC4 cells proliferated with DHT stimulation. Enzalutamide treatment abolished DHT-induced AR activation (Fig. S1 D and E) and resensitized the cells to docetaxel in the presence of DHT (Fig. 1D) , suggesting that the involvement of AR signaling in DHT modulated docetaxel resistance in LAPC4.
Taken together, these data demonstrate a role of AR signaling in docetaxel sensitivity in LAPC4, implying that modulating AR signaling significantly impacts docetaxel sensitivity in some hormonesensitive prostate cancer cell lines.
KDM5D as a Potential Mediator of Docetaxel Sensitivity with DHT Stimulation. We speculated that the differential docetaxel sensitivity in response to DHT treatment between LNCaP and LAPC4 may be due to differences in their AR transcriptomes. Based on RNA-seq analysis of these cell lines, we found that LNCaP and LAPC4 have distinct AR transcriptomes after DHT exposure, as shown in Fig. 2A . Gene ontology (GO) term analysis of the DHTregulated genes from the RNA-seq data highlighted varied gene sets regulated by DHT in these cell lines (Fig. S2A) . Given multiple reports implicating epigenetic modulators affecting AR signaling (7-9), we hypothesized that epigenetic modulators may play a role in the differential gene expression profiles in response to DHT exposure in these cell lines and in turn determine docetaxel sensitivity. We therefore compared the expression level of 236 genes from the RNA-seq data, which were represented in four epigenetic GO terms (i.e., GO:0016573 histone acetylation, GO:0016575 histone deacetylation, GO:0016571 histone methylation, and GO:0016577 histone demethylation) to assess whether any of these functions were associated with the differential docetaxel sensitivity in response to DHT (Fig. S2B) . A stringent threshold by Bonferroni-corrected P value and twofold gene expression difference identified seven differentially expressed genes as potential candidates (Fig. 2B ) involved in DHT-induced docetaxel insensitivity in LAPC4 but not LNCaP. Knockdown of these seven genes by siRNA (small-interfering RNA) was performed in LNCaP or LAPC4, based on the expression of the relevant gene. Of the seven genes, only knockdown of KDM5D in LNCaP significantly altered docetaxel sensitivity in the presence of 10 nM DHT compared with an siRNA negative control [GI 50 10.46 ± 1.27 and 1.28 ± 0.79 nM in si-KDM5D and si-control, respectively, logtwofold change (Log2FC) 3.19 ± 0.74] (Fig. 2C) .
To determine whether KDM5D altered docetaxel sensitivity through AR signaling, we examined DU145, an AR-negative cell line, with knockdown of KDM5D. Nuclear protein was extracted to examine KDM5D expression levels because of nonspecific affinity in cytoplasmic protein. As expected, knockdown of KDM5D in LNCaP rendered these cells less sensitive to docetaxel with DHT (GI 50 10.14 ± 1.63 and 1.00 ± 0.33 nM in si-KDM5D and si-control, respectively, Log2FC 3.37 ± 0.25) but not without DHT (GI 50 7.21 ± 1.43 and 6.89 ± 0.71 nM in si-KDM5D and si-control, respectively, Log2FC 0.06 ± 0.14), whereas knockdown of KDM5D in DU145 did not alter these cells' sensitivity to docetaxel in the presence (GI 50 4.00 ± 0.14 and 4.20 ± 0.26 nM in si-KDM5D and si-control, respectively, Log2FC −0.07 ± 0.14) or absence (GI 50 3.73 ± 0.06 and 3.24 ± 0.06 nM in si-KDM5D and si-control, respectively, Log2FC 0.20 ± 0.05) of DHT ( Fig. 2D ), suggesting that both AR signaling and lower expression of KDM5D are involved in docetaxel sensitivity.
Similarly, relative resistance to docetaxel was also observed in LNCaP with stable knockdown of KDM5D generated by Tet-on inducible short hairpin (sh)-KDM5D (Fig. S2C) , and overexpressing KDM5D in LAPC4 by lentiviral infection reversed docetaxel insensitivity with DHT stimulation (Fig. S2D) . Collectively, these data suggest that KDM5D plays an important role in docetaxel resistance, potentially by altering expression of AR target genes.
KDM5D and AR in the Nucleus Cooperate in Rendering Docetaxel
Sensitivity. With regard to the specificity of the interaction between KDM5D and AR in docetaxel sensitivity, we used the PC3 cell line, which is AR-negative and has been reported to have deletion of the KDM5D region on the Y chromosome in publicly available datasets (Fig. S3) . To test the hypothesis that KDM5D modulates docetaxel sensitivity with AR activity in the nucleus, stable KDM5D-overexpressing PC3 cells were generated. We then examined whether introducing AR-FL (full length) and its truncated splice isoform AR-v7 into these cells affects docetaxel sensitivity with and without DHT stimulation. As shown in Fig. 3A , AR-FL introduction into control PC3, which has loss of KDM5D, resulted in greater docetaxel resistance with DHT stimulation but not without DHT stimulation, whereas introduction of AR-v7, which has been shown to be constitutively active (10) docetaxel insensitivity regardless of DHT stimulation. Notably, in the PC3-KDM5D-overexpressing cell line, docetaxel insensitivity was not seen with either AR-FL or AR-v7 introduction.
To assess whether KDM5D affects the expression level of AR, we examined AR expression in the nucleus with and without DHT stimulation. As expected, the expression level of AR-FL in the nucleus was increased with DHT stimulation whereas AR-v7 was consistently sustained in the nucleus, indicating a constitutively active state (Fig. 3B) . Importantly, KDM5D introduction into PC3 cells did not alter AR expression levels. These data suggest that KDM5D mediates AR transcriptional activity in the nucleus, which consequently causes varied docetaxel sensitivity.
KDM5D Directly Interacts with AR and Regulates Its Transcriptional
Activity. To examine whether KDM5D interacts with AR or AR-associated machinery, coimmunoprecipitation (co-IP) of nuclear protein was conducted using a KDM5D-Flag-tagged LAPC4 cell line, and we found that ectopic KDM5D expression directly interacts with AR in the nucleus (Fig. S4A) . Furthermore, endogenous interaction between KDM5D and AR was confirmed in LNCaP, as there was a weaker co-IP with knockdown of KDM5D (Fig. 4A) . This result suggests a physical interaction between KDM5D and AR in the nucleus.
To determine the significance of the KDM5D interaction with AR, we used quantitative PCR (QT-PCR) to assess the expression levels of several known androgen-regulated genes in LNCaP cells with and without KDM5D knockdown (Fig. 4B ) and in the KDM5D-overexpressed Flag-tagged LAPC4 cell line (Fig. S4B) . KDM5D expression impacted androgen-responsive genes with DHT stimulation, demonstrating a relationship between KDM5D and AR signaling.
Because KDM5D has been shown to be capable of demethylating H3K4me3 and me2 marks (11, 12) , we examined whether knockdown of KDM5D increases the H3K4me3 level of promoter regions in AR-regulated genes and affects AR binding to its binding sites with DHT stimulation. As shown in Fig. 4C , H3K4me3 levels in the promoter regions of AR-regulated genes were increased by knockdown of KDM5D, and AR binding to those promoter regions was more prominent with DHT stimulation, suggesting that knockdown of KDM5D increases H3K4me3 marks, which are recognized as active transcription marks enhancing AR transcriptional activity. We also conducted RNA-seq analysis using LNCaP sh-control and sh-KDM5D. With knockdown of KDM5D, there were a number of AR-regulated genes whose expression was altered compared with control ( Fig. 4D) , suggesting its potential role in modulating the AR transcriptome. Because LNCaP sh-control was sensitive to docetaxel in charcoal-stripped serum (CSS) supplemented with 10 nM DHT, and LNCaP sh-KDM5D became less sensitive to docetaxel in the same culture medium (Fig. S2C) , we performed gene set enrichment analysis (GSEA) in LNCaP sh-control and sh-KDM5D to assess which pathways were up-or down-regulated by knockdown of KDM5D. Seventy-three gene sets were significantly enriched at false discovery rate (FDR) <0.25 (Fig.  S4C) ; most notably, the mitosis/cell cycle-related pathways were the most significantly up-regulated gene sets ( Fig. 4E and Fig. S4D ). Collectively, these data suggest that KDM5D interacts with AR in the nucleus, regulating its transcriptional activity by demethylating H3K4me3 active transcription marks, and that reduced expression of KDM5D leads to altered regulation of AR activity, which in turn confers docetaxel insensitivity.
Impact of KDM5D Expression on Docetaxel Sensitivity in LNCaP Sublines
and Impact on Clinical Outcomes. Because KDM5D expression level seemed to be involved in docetaxel sensitivity, this was examined in a panel of prostate cancer cell lines. Interestingly, QT-PCR showed a lack of KDM5D expression in LAPC4, LNCaP-104R2, and PC3 (Fig. S5A) . We examined whether LAPC4 and LNCaP-104R2 have a deletion in the KDM5D region on the Y chromosome similar to PC3 (Fig. S3) . MCF7, which has a 22XX karyotype, was used as a negative control. We confirmed the absence of the KDM5D region in all these cell lines (Fig. 5A) . We then explored docetaxel sensitivity in LNCaP-derived CRPC cell lines expressing AR with and without KDM5D (Fig. 5B, Left Upper) . Specifically the LNCaP-104R2 cell line, which has loss of KDM5D, became less sensitive to docetaxel with DHT stimulation (Fig. 5B, Lower) . Clonogenic assays showed that the parental LNCaP treated with 10 nM docetaxel in DHT-supplemented medium did not grow, whereas LNCaP-104R2 kept growing in the presence of DHT and docetaxel (Fig.  5B, Right Upper) . These data suggest that KDM5D loss with DHT stimulation permits survival in the presence of docetaxel and is a possible cause of docetaxel resistance in CRPC.
To start to assess the clinical relevance of these results, we analyzed publicly available gene expression profile data from the Oncomine database. The data from LNCaP and LNCaP-derived CRPC cell lines suggest that there may be genetic loss of KDM5D during ADT, which may lead to docetaxel resistance. We hypothesized that CRPC patients have attenuated KDM5D expression levels compared with hormone-naïve primary cancer patients. KDM5D RNA expression data were available in eight cohorts (13) (14) (15) (16) (17) (18) (19) (20) . Seven of the eight cohorts showed decreased expression levels of KDM5D in CRPC compared with hormone-naïve primary cancer, five of which were significantly decreased (Fig.  5C, Left) , and two of the remaining three cohorts with smaller sample sizes also showed a similar trend of KDM5D expression level (Fig. S5B) . One of the eight cohorts, the Grasso cohort, extensively investigated copy-number alteration (CNA) in primary cancer (11 patients) and CRPC (48 patients). Thirteen of 48 CRPC patients (27.1%) had KDM5D deletion, whereas no patients with primary tumors had KDM5D deletion (Fig. S5C ).
Of the 31 CRPC patients with gene expression profiling, we found a significant correlation between KDM5D mRNA expression level and CNA after determining the exon coverage ratio, indicating that less KDM5D expression in CRPC tumors is likely attributable to genetic alteration than epigenetic silencing or posttranslational modification (Fig. 5C, Right Upper) . Notably, patients with decreased expression of KDM5D in their CRPC tumors had significantly shorter OS from time of diagnosis (Fig. 5C , Right Lower and Fig. S5D ). In this small cohort of 31 patients, there was a trend toward shorter survival from time of chemotherapy initiation with lower KDM5D expression (Fig. S5E) . We also determined whether there was a correlation between AR and KDM5D expression levels, but no significant correlation was seen in three independent cohorts (Fig. S5F) , suggesting that aberrations of AR and attenuated KDM5D expression in CRPC are independent events. Further study to define the predictive value of KDM5D expression for docetaxel sensitivity is required. Taken together, these data suggest that KDM5D is an important determinant of AR activity and in turn impacts docetaxel sensitivity in vitro, and that deletion or attenuated KDM5D expression in patients may be associated with poorer clinical outcomes.
Discussion
The specificity of AR signaling is determined by multiple factors, including epigenetic factors, but it is clear that these changes are associated with different disease transitions including tumorigenesis (21), development of CRPC (22), and potentially drug resistance. KDM5D has been reported to have a tumor suppressor function in prostate cancer (23) . Specifically, KDM5D regulates invasion-associated genes (such as the MMP family), demethylating their H3K4me3 marks, and loss of KDM5D causes the cell to acquire invasiveness with increased H3K4me3 levels in the promoter regions of relevant genes, leading to the development of metastasis. This work focused on AR-negative CRPC cell lines, such as DU145 and PC3. Our work further documents the biological relevance of KDM5D in prostate cancer, as we show that KDM5D interacts with and alters the transcriptional activity of AR and impacts docetaxel sensitivity.
Preclinical and clinical experience has documented minimal activity of taxane therapy alone in HSPC (24, 25) , and transcriptional response to this drug has recently been shown to be largely dependent on hormone status (26) , suggesting that specific AR signaling modulates docetaxel insensitivity and that alteration of this signaling might sensitize prostate cancer cells to docetaxel. One well-known feature of AR signaling in prostate cancer involves ERG, which is overexpressed in at least 50% of prostate cancers as a result of gene fusions with genes such as TMPRSS2, SLC45A3, and NDRG1, which have AR promoter regions (27, 28) . ERG has recently been shown to bind to soluble tubulin in the cytoplasm and antagonize inhibition of microtubule depolymerization by taxanes, resulting in its resistance to this therapy (29) . In this paper, we studied LNCaP and LAPC4, hormone-sensitive prostate cancer cell lines, both of which are ERG fusion-negative, and demonstrated that LAPC4, which does not express KDM5D, displayed docetaxel resistance with androgen exposure and also showed the converse, in that blocking AR signaling with enzalutamide sensitized LAPC4 cells to docetaxel. On the other hand, LNCaP, which expresses KDM5D, did not show any change in docetaxel sensitivity upon androgen exposure. These data suggest that KDM5D expression in mHSPC patients could serve as a biomarker predicting docetaxel sensitivity, and may identify which patients with mHSPC (i.e., those with low KDM5D) might benefit from docetaxel treatment given at the time of ADT initiation.
The greater benefit of adding docetaxel to ADT for mHSPC (i.e., CHAARTED trial) than for CRPC patients suggests that initiation of ADT results in a series of transcriptional changes leading to greater docetaxel activity and that these changes are less common in the CRPC setting when docetaxel is added after prolonged ADT (3). In our study, we demonstrated that among 10 prostate cancer cell lines, 3 cell lines, LAPC4, PC3, and LNCaP-104R2, have genetic loss of KDM5D. KDM5D deletion in LNCaP-104R2, a LNCaP-derived CRPC cell line, suggests that deletion may occur during ADT. Our analysis of publicly available clinical datasets detailed less KDM5D RNA expression in CRPC compared with hormone-sensitive primary cancer and, in the Grasso cohort, which extensively studied the CNA of CRPC patients, we found that 13 out of 48 (27.1%) CRPC patients exhibited KDM5D deletion. These data indicate that decreased KDM5D expression level in CRPC may in part be due to KDM5D deletion as well as other processes that suppress gene expression such as epigenetic silencing and posttranslational modification, which could occur during ADT. Furthermore, we demonstrated that with AR activation, KDM5D transcript expression in multiple prostate cancer studies from the Oncomine database. Datasets were analyzed for KDM5D expression in primary prostate cancer versus CRPC. Statistical significance and number of samples are indicated. P values were calculated using two-sample, one-tailed Welch's t test. In the Grasso cohort, 31 out of the 35 CRPC patients had exon coverage ratio, mRNA expression level, and clinical outcome data (overall survival). Linear regression was performed to examine a correlation between exon coverage ratio and mRNA expression level, and patients were divided into two groups according to KDM5D mRNA expression level to carry out Kaplan-Meier analysis. P value is calculated using log-rank test. Median survival was 120 and 46.5 mo, respectively, for high-KDM5D and low-KDM5D groups.
LNCaP-104R2, which has genetic loss of KDM5D, exhibited docetaxel insensitivity compared with parental LNCaP and other LNCaP-derived CRPC cell lines. The potentially more aggressive biology of prostate cancer cells with low KDM5D expression is supported by a higher frequency of loss of KDM5D in CRPC than primary prostate cancer and shorter OS in patients with lower KDM5D expression in the Grasso cohort. Given that CRPC patients have less KDM5D expression and that 62.7% of CRPC patients harbor aberrations of AR signaling (5), this may explain why docetaxel may have less activity in CRPC; namely, altered AR signaling and low KDM5D may be the cause of less docetaxel activity in CRPC than when docetaxel is added at the start of ADT in mHSPC. Hypothetically, patients with CRPC and persistent AR activity but low KDM5D may benefit more from a combination of further androgen blockade (with an agent such as enzalutamide) and docetaxel rather than docetaxel alone. This hypothesis requires testing.
In conclusion, KDM5D encoded on the Y chromosome affects AR signaling and impacts docetaxel sensitivity. Further study to explore this biological mechanism and the predictive value of KDM5D expression on docetaxel sensitivity is required, and has the potential to provide new insights into docetaxel resistance and guide strategies to improve its efficacy.
Materials and Methods
Cell Lines, Proliferation Assay, and Clonogenic Survival Assay. The prostate cancer cell lines (LNCaP, 22RV1, VCAP, PC3, and DU145) were obtained from the American Type Culture Collection (ATCC). The LNCaP-Abl cell line was provided by Zoran Culig (Innsbruck Medical University, Innsbruck, Austria). The LNCaP-C42 cell line was obtained from ViroMed Laboratories. The LNCaP-104R2 cell line was provided by Shutsung Liao (University of Chicago, Chicago, IL), and the LAPC-4 cell line was provided by Charles Sawyers (Memorial Sloan Kettering Cancer Center, New York, NY). These cells were maintained with 10% FBS (LNCaP, LNCaP-C42, LNCaP-AI, VCAP, 22RV1, LAPC4, PC3, and DU145) or 10% charcoal-stripped serum (LNCaP-Abl and LNCaP-104R2) at 37°C in 5% CO 2 . Cells treated in individual experiments were assessed for cell viability using CellTiter-Glo Luminescent Assay (Promega) following the manufacturer's protocol by incubating cells in a 96-well format in 1:1 media to luminescent reagent for 10 min. Additional information can be found in SI Materials and Methods.
QT-PCR, DNA Extraction, and RNA-Seq Library Preparation. The primers used are listed in Dataset S1. Additional information can be found in SI Materials and Methods. For RNA-seq, polyA+ RNA was purified using a polyA Spin mRNA Isolation Kit (New England Biolabs) followed by library preparation for 40 ng of purified RNA. Additional information regarding library preparation can be found in SI Materials and Methods. Biological triplicates were sequenced by Illumina NextSeq 500 (SR75) at the Dana-Farber Cancer Institute Center for Cancer Computational Biology Core Facility.
RNA Interference, DNA Transfection, and Lentiviral Transduction. Sequences of short hairpin RNAs (shRNAs) used are listed in Dataset S2. siRNAs targeting genes of interest (ON-TARGETplusTM siRNA) were purchased from Dharmacon (catalog numbers are listed in Dataset S2). The AR isoform plasmid was generously provided by S. Plymate (University of Washington, Seattle, WA), and the construct was subcloned into pHR′-CMV-GFP expression vector. Additional information can be found in SI Materials and Methods.
Immunoblotting, Cell Fractionation, and Coimmunoprecipitation. The cellular protein fractionation protocol can be found in SI Materials and Methods. Details of immunoprecipitation can be found in SI Materials and Methods. Antibodies used are listed in Table S1 .
Chromatin Immunoprecipitation. Chromatin equivalent to 7.5 × 10 6 cells was used for chromatin immunoprecipitation (ChIP) using various antibodies (listed in Table S1 ). Extracted ChIP-DNA was used for quantitative PCR (qPCR) with the specific primers as listed in Dataset S1. Additional information can be found in SI Materials and Methods. 
